Wells Fargo
ACAD icon

Wells Fargo’s Acadia Pharmaceuticals ACAD Stock Holding History

Wells Fargo’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,000
Closed -$129K – 6842
2021
Q1 		$129K Buy
+5,000
New +$220K ﹤0.01% 5367

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo's ACAD Position: Q2 2026 in Review

Wells Fargo increased its Acadia Pharmaceuticals (ACAD) stake by 65% in Q2 2026, buying an estimated $1.69M and bringing the position to 195,371 shares worth $4.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2858.

Wells Fargo first reported a position in ACAD in Q2 2013 and has held it in 53 quarters since. The position peaked at $10.6M in Q2 2020. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Wells Fargo held 195,371 shares of Acadia Pharmaceuticals worth $4.94M as of Q2 2026.
  • Wells Fargo bought 76,846 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.69M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2858 holding.
  • Wells Fargo first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Acadia Pharmaceuticals position peaked at $10.6M in Q2 2020.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.